CD1C and non-small cell lung carcinoma: Another interesting trial [38] was a randomized phase II study investigating SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1) +/CD141 (BDCA-3) + myeloid dendritic cells in oligoprogressive solid tumors, also NSCLC, refractory to anti PD-1 ICB.